Search

Your search keyword '"Holmøy, Trygve"' showing total 286 results
Start Over Author "Holmøy, Trygve" Search Limiters Full Text
286 results on '"Holmøy, Trygve"'

6. Repeat expansions in AR, ATXN1, ATXN2 and HTT in Norwegian patients diagnosed with amyotrophic lateral sclerosis

Author

Novy, Camilla, primary, Busk, Øyvind L, additional, Tysnes, Ole-Bjørn, additional, Landa, Sigve S, additional, Aanjesen, Tori N, additional, Alstadhaug, Karl B, additional, Bjerknes, Tale L, additional, Bjørnå, Ingrid K, additional, Bråthen, Geir, additional, Dahl, Elin, additional, Demic, Natasha, additional, Fahlström, Maria, additional, Flemmen, Heidi Ø, additional, Hallerstig, Erika, additional, HogenEsch, Ineke, additional, Kampman, Margitta T, additional, Kleveland, Grethe, additional, Kvernmo, Helene B, additional, Ljøstad, Unn, additional, Maniaol, Angelina, additional, Morsund, Aase Hagen, additional, Nakken, Ola, additional, Olsen, Cathrine G, additional, Schlüter, Katrin, additional, Utvik, May-Sissel, additional, Yaseen, Ryaz, additional, Holla, Øystein L, additional, Holmøy, Trygve, additional, and Høyer, Helle, additional

Published
2024
Full Text
View/download PDF

11. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease

Author

Ueland, Grethe Åstrøm, primary, Ueland, Hans Olav, additional, Stokland, Ann-Elin Meling, additional, Bhan, Alok, additional, Schønberg, Anne, additional, Sollid, Stina T, additional, Morgas, Dina Edvarda, additional, Holmøy, Trygve, additional, Lima, Kari, additional, Methlie, Paal, additional, Løvås, Kristian, additional, Torkildsen, Øivind, additional, and Husebye, Eystein S, additional

Published
2023
Full Text
View/download PDF

12. T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis

Author

Wolf, Asia-Sophia, primary, Ravussin, Anthony, additional, König, Marton, additional, Øverås, Mathias H., additional, Solum, Guri, additional, Kjønstad, Ingrid Fadum, additional, Chopra, Adity, additional, Holmøy, Trygve, additional, Harbo, Hanne F., additional, Syversen, Silje Watterdal, additional, Jørgensen, Kristin Kaasen, additional, Høgestøl, Einar August, additional, Vaage, Jon Torgils, additional, Celius, Elisabeth G., additional, Lund-Johansen, Fridtjof, additional, Munthe, Ludvig A., additional, Nygaard, Gro Owren, additional, and Mjaaland, Siri, additional

Published
2023
Full Text
View/download PDF

13. A Novel SPAST Variant Associated with Isolated Spastic Paraplegia.

Author

Høyer, Helle, Nakken, Ola, and Holmøy, Trygve

Subjects
FAMILIAL spastic paraplegia, PARAPLEGIA, MAGNETIC resonance imaging, GENETIC variation, MOTOR neurons, SPINAL cord
Abstract

Genetic variants in SPAST are the most common cause of hereditary spastic paraplegia (HSP), entitled spastic paraplegia type 4 (SPG4). Inheritance is autosomal dominant, and age of onset can vary from childhood to adulthood. Pathogenic SPAST variants are often observed in isolated cases, likely due to reduced penetrance and clinical variability. We report an isolated case of SPG4 associated with a novel likely pathogenic variant in SPAST. A 38-year-old woman presented with an eight-year history of progressive difficulty walking. Neurological examination revealed spastic paraparesis in the absence of upper motor neuron dysfunction, sensory deficits, or intellectual disability. Magnetic resonance imaging (MRI) of the brain and spinal cord was normal. No family members had similar complaints. Genetic analysis revealed a novel heterozygous sequence variant in SPAST, c.1751A > G p.(Asp584Gly) (NM_014946.4). The affected amino acid is highly conserved among orthologue and paralogue species. Four other nucleotide substitutions predicted to affect the same amino acid, a "hot spot", have been reported previously in adult-onset HSP. This report describes a novel SPAST variant in a female with HSP without a known family history of the disorder. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Prevalence and Characteristics Associated With Post–COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults

Author

Selvakumar, Joel, primary, Havdal, Lise Beier, additional, Drevvatne, Martin, additional, Brodwall, Elias Myrstad, additional, Lund Berven, Lise, additional, Stiansen-Sonerud, Tonje, additional, Einvik, Gunnar, additional, Leegaard, Truls Michael, additional, Tjade, Trygve, additional, Michelsen, Annika E., additional, Mollnes, Tom Eirik, additional, Lund-Johansen, Fridtjof, additional, Holmøy, Trygve, additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, Sandler, Carolina X., additional, Cvejic, Erin, additional, Lloyd, Andrew R., additional, and Wyller, Vegard Bruun Bratholm, additional

Published
2023
Full Text
View/download PDF

20. The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis

Author

Lie, Ingrid Anne, primary, Wesnes, Kristin, additional, Kvistad, Silje S., additional, Brouwer, Iman, additional, Wergeland, Stig, additional, Holmøy, Trygve, additional, Midgard, Rune, additional, Bru, Alla, additional, Edland, Astrid, additional, Eikeland, Randi, additional, Gosal, Sonia, additional, Harbo, Hanne F., additional, Kleveland, Grethe, additional, Sørenes, Yvonne S., additional, Øksendal, Nina, additional, Barkhof, Frederik, additional, Vrenken, Hugo, additional, Myhr, Kjell-Morten, additional, Bø, Lars, additional, and Torkildsen, Øivind, additional

Published
2022
Full Text
View/download PDF

23. Clinical trials in pediatric ALS: a TRICALS feasibility study

Author

Kliest, Tessa, Van Eijk, Ruben P.A., Al-Chalabi, Ammar, Albanese, Alberto, Andersen, Peter M., Amador, Maria Del Mar, Bråthen, Geir, Brunaud-Danel, Veronique, Brylev, Lev, Camu, William, De Carvalho, Mamede, Cereda, Cristina, Cetin, Hakan, Chaverri, Delia, Chiò, Adriano, Corcia, Philippe, Couratier, Philippe, De Marchi, Fabiola, Desnuelle, Claude, Van Es, Michael A., Esteban, JesÚs, Filosto, Massimiliano, GarcÍa Redondo, Alberto, Grosskreutz, Julian, Hanemann, Clemens O., Holmøy, Trygve, Høyer, Helle, Ingre, Caroline, Koritnik, Blaz, Kuzma-Kozakiewicz, Magdalena, Lambert, Thomas, Leigh, Peter N., Lunetta, Christian, Mandrioli, Jessica, Mcdermott, Christopher J., Meyer, Thomas, Mora, Jesus S., Petri, Susanne, Povedano, Mónica, Reviers, Evy, Riva, Nilo, Roes, Kit C.B., Rubio, Miguel Á., Salachas, François, Sarafov, Stayko, Sorarù, Gianni, Stevic, Zorica, Svenstrup, Kirsten, Møller, Anette Torvin, Turner, Martin R., Van Damme, Philip, Van Leeuwen, Lucie A.G., Varona, Luis, VÁzquez Costa, Juan F., Weber, Markus, Hardiman, Orla, Van Den Berg, Leonard H., Kliest, Tessa, Van Eijk, Ruben P.A., Al-Chalabi, Ammar, Albanese, Alberto, Andersen, Peter M., Amador, Maria Del Mar, Bråthen, Geir, Brunaud-Danel, Veronique, Brylev, Lev, Camu, William, De Carvalho, Mamede, Cereda, Cristina, Cetin, Hakan, Chaverri, Delia, Chiò, Adriano, Corcia, Philippe, Couratier, Philippe, De Marchi, Fabiola, Desnuelle, Claude, Van Es, Michael A., Esteban, JesÚs, Filosto, Massimiliano, GarcÍa Redondo, Alberto, Grosskreutz, Julian, Hanemann, Clemens O., Holmøy, Trygve, Høyer, Helle, Ingre, Caroline, Koritnik, Blaz, Kuzma-Kozakiewicz, Magdalena, Lambert, Thomas, Leigh, Peter N., Lunetta, Christian, Mandrioli, Jessica, Mcdermott, Christopher J., Meyer, Thomas, Mora, Jesus S., Petri, Susanne, Povedano, Mónica, Reviers, Evy, Riva, Nilo, Roes, Kit C.B., Rubio, Miguel Á., Salachas, François, Sarafov, Stayko, Sorarù, Gianni, Stevic, Zorica, Svenstrup, Kirsten, Møller, Anette Torvin, Turner, Martin R., Van Damme, Philip, Van Leeuwen, Lucie A.G., Varona, Luis, VÁzquez Costa, Juan F., Weber, Markus, Hardiman, Orla, and Van Den Berg, Leonard H.

Abstract

Background: Pediatric investigation plans (PIPs) describe how adult drugs can be studied in children. In 2015, PIPs for Amyotrophic Lateral Sclerosis (ALS) became mandatory for European marketing-authorization of adult treatments, unless a waiver is granted by the European Medicines Agency (EMA). Objective: To assess the feasibility of clinical studies on the effect of therapy in children (<18 years) with ALS in Europe. Methods: The EMA database was searched for submitted PIPs in ALS. A questionnaire was sent to 58 European ALS centers to collect the prevalence of pediatric ALS during the past ten years, the recruitment potential for future pediatric trials, and opinions of ALS experts concerning a waiver for ALS. Results: Four PIPs were identified; two were waived and two are planned for the future. In total, 49 (84.5%) centers responded to the questionnaire. The diagnosis of 44,858 patients with ALS was reported by 46 sites; 39 of the patients had an onset < 18 years (prevalence of 0.008 cases per 100,000 or 0.087% of all diagnosed patients). The estimated recruitment potential (47 sites) was 26 pediatric patients within five years. A majority of ALS experts (75.5%) recommend a waiver should apply for ALS due to the low prevalence of pediatric ALS. Conclusions: ALS with an onset before 18 years is extremely rare and may be a distinct entity from adult ALS. Conducting studies on the effect of disease-modifying therapy in pediatric ALS may involve lengthy recruitment periods, high costs, ethical/legal implications, challenges in trial design and limited information.

Published
2022
Full Text
View/download PDF

41. Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab

Author

Holmøy, Trygve, Torkildsen, Øivind, and Zarnovicky, Svetozar

Subjects
Article Subject
Abstract

During treatment with fingolimod, B cells are redistributed from blood to secondary lymphoid organs, where they are protected from the effect of anti-CD20 and other cell-depleting therapies. We describe a multiple sclerosis patient who had almost complete depletion of B cells in blood during and shortly after treatment with fingolimod. He developed severe disease activity resembling immune reconstitution syndrome after switching from fingolimod to rituximab, with first dose being six weeks after fingolimod cessation. Following recommendations from the Swedish MS Association, rituximab treatment was started as one single dose of 1000 mg. In patients treated with fingolimod, pathogenic B cells may still be sequestered in secondary lymph nodes if this dose is given early. To deplete such B cells as they egress from the lymph nodes, we propose that a second dose of rituximab a few weeks after the first dose should be considered.

Published
2018
Full Text
View/download PDF

46. CD4+ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid.

Author

Høglund, Rune A., Bremel, Robert D., Homan, E. Jane, Torsetnes, Silje Bøen, Lossius, Andreas, and Holmøy, Trygve

Subjects
B cell receptors, CEREBROSPINAL fluid, T cells, BLOOD cells, IMMUNOGLOBULIN idiotypes
Abstract

B cells are important pathogenic players in multiple sclerosis (MS), but their exact role is not known. We have previously demonstrated that B cells from cerebrospinal fluid (CSF) of MS patients can activate T cells that specifically recognize antigenic determinants (idiotopes) from their B cell receptors (BCRs). The aim of this study was to evaluate whether in silico prediction models could identify antigenic idiotopes of immunoglobulin heavy-chain variable (IGHV) transcriptomes in MS patients. We utilized a previously assembled dataset of CSF IGHV repertoires from MS patients. To guide selection of potential antigenic idiotopes, we used in silico predicted HLA-DR affinity, endosomal processing, as well as transcript frequency from nine MS patients. Idiotopes with predicted low affinity and low likelihood of cathepsins cleavage were inert controls. Peripheral blood mononuclear cells from these patients were stimulated with the selected idiotope peptides in presence of anti-CD40 for 12 h. T cells were then labeled for activation status with anti-CD154 antibodies and CD3+CD4+ T cells phenotyped as memory (CD45RO+) or naïve (CD45RO−), with potential for brain migration (CXCR3 and/or CCR6 expression). Anti-CD14 and -CD8 were utilized to exclude monocytes and CD8+ T cells. Unstimulated cells or insulin peptides were negative controls, and EBNA-1 peptides or CD3/CD28 beads were positive controls. The mean proportion of responding memory CD4+ T cells from all nine MS patients was significantly higher for idiotope peptides with predicted high HLA-DR affinity and high likelihood of cathepsin cleavage, than toward predicted inert peptides. Responses were mainly observed toward peptides affiliated with the CDR3 region. Activated memory CD4+ T cells expressed the chemokine receptor CCR6, affiliated with a Th17 phenotype and allowing passage into the central nervous system (CNS). This in vitro study suggests that that antigenic properties of BCR idiotopes can be identified in silico using HLA affinity and endosomal processing predictions. It further indicates that MS patients have a memory T cell repertoire capable of recognizing frequent BCR idiotopes found in endogenous CSF, and that these T cells express chemokine receptors allowing them to reach the CSF B cells expressing these idiotopes. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation : a large multinational screening study

Author

Nordin, Angelica, Akimoto, Chizuru, Wuolikainen, Anna, Alstermark, Helena, Forsberg, Karin, Baumann, Peter, Pinto, Susana, de Carvalho, Mamede, Hübers, Annemarie, Nordin, Frida, Ludolph, Albert C., Weishaupt, Jochen H., Meyer, Thomas, Grehl, Torsten, Schweikert, Kathi, Weber, Markus, Burkhardt, Christian, Neuwirth, Christoph, Holmøy, Trygve, Morita, Mitsuya, Tysnes, Ole-Bjørn, Benatar, Michael, Wuu, Joanne, Lange, Dale J., Bisgård, Carsten, Asgari, Nasrin, Tarvainen, Ilkka, Brännström, Thomas, Andersen, Peter M., Nordin, Angelica, Akimoto, Chizuru, Wuolikainen, Anna, Alstermark, Helena, Forsberg, Karin, Baumann, Peter, Pinto, Susana, de Carvalho, Mamede, Hübers, Annemarie, Nordin, Frida, Ludolph, Albert C., Weishaupt, Jochen H., Meyer, Thomas, Grehl, Torsten, Schweikert, Kathi, Weber, Markus, Burkhardt, Christian, Neuwirth, Christoph, Holmøy, Trygve, Morita, Mitsuya, Tysnes, Ole-Bjørn, Benatar, Michael, Wuu, Joanne, Lange, Dale J., Bisgård, Carsten, Asgari, Nasrin, Tarvainen, Ilkka, Brännström, Thomas, and Andersen, Peter M.

Abstract

A large GGGGCC-repeat expansion mutation (HREM) in C9orf72 is the most common known cause of ALS and FTD in European populations. Sequence variations immediately downstream of the HREM region have previously been observed and have been suggested to be one reason for difficulties in interpreting RP-PCR data. Our objective was to determine the properties of these sequence variations with regard to prevalence, the range of variation, and effect on disease prognosis. We screened a multi-national cohort (n = 6981) for the HREM and samples with deviant RP-PCR curves were identified. The deviant samples were subsequently sequenced to determine sequence alteration. Our results show that in the USA and European cohorts (n = 6508) 10.7% carried the HREM and 3% had a sequence variant, while no HREM or sequence variants were observed in the Japanese cohort (n = 473). Sequence variations were more common on HREM alleles; however, certain population specific variants were associated with a non-expanded allele. In conclusion, we identified 38 different sequence variants, most located within the first 50 bp downstream of the HREM region. Furthermore, the presence of an HREM was found to be coupled to a lower age of onset and a shorter disease survival, while sequence variation did not have any correlation with these parameters.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results